BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 17239341)

  • 21. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression.
    Brechter AB; Lerner UH
    Arthritis Rheum; 2007 Mar; 56(3):910-23. PubMed ID: 17328065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
    Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
    Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chloroform extract of deer antler inhibits osteoclast differentiation and bone resorption.
    Li YJ; Kim TH; Kwak HB; Lee ZH; Lee SY; Jhon GJ
    J Ethnopharmacol; 2007 Sep; 113(2):191-8. PubMed ID: 17646068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Regulatory mechanisms of osteoclast differentiation and function].
    Takahashi N
    Clin Calcium; 2006 Jun; 16(6):940-47. PubMed ID: 16751689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos.
    Ha J; Choi HS; Lee Y; Lee ZH; Kim HH
    Int Immunopharmacol; 2009 Jun; 9(6):774-80. PubMed ID: 19285574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPalpha-interaction.
    Lundberg P; Koskinen C; Baldock PA; Löthgren H; Stenberg A; Lerner UH; Oldenborg PA
    Biochem Biophys Res Commun; 2007 Jan; 352(2):444-8. PubMed ID: 17126807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone metastasis: can osteoclasts be excluded?
    Martin TJ; Mundy GR
    Nature; 2007 Feb; 445(7130):E19; discussion E19-20. PubMed ID: 17314931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitogen-activated protein kinases mediate interleukin-1beta-induced receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells.
    Oikawa A; Kobayashi M; Okamatsu Y; Shinki T; Kamijo R; Yamamoto M; Hasegawa K
    J Periodontal Res; 2007 Aug; 42(4):367-76. PubMed ID: 17559635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Active caspase-3 is required for osteoclast differentiation.
    Szymczyk KH; Freeman TA; Adams CS; Srinivas V; Steinbeck MJ
    J Cell Physiol; 2006 Dec; 209(3):836-44. PubMed ID: 16972256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition effect of enteropeptidase on RANKL-RANK signalling by cleavage of RANK.
    Zhao Y; Jin M; Ma J; Zhang S; Li W; Chen Y; Zhou Y; Tao H; Liu Y; Wang L; Han H; Niu G; Tao H; Liu C; Gao B
    FEBS Lett; 2013 Sep; 587(18):2958-64. PubMed ID: 23954298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
    Tsuji-Naito K
    Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteoclast culture and resorption assays.
    Bradley EW; Oursler MJ
    Methods Mol Biol; 2008; 455():19-35. PubMed ID: 18463808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Genomic approaches to bone and joint diseases. Mutations of RANK, OPG and RANKL genes found in humans].
    Kobayashi Y; Takahashi N
    Clin Calcium; 2008 Feb; 18(2):202-9. PubMed ID: 18245890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated platelets retain their potential to induce osteoclast-like cell formation in murine bone marrow cultures.
    Maitz P; Kandler B; Fischer MB; Watzek G; Gruber R
    Platelets; 2006 Nov; 17(7):477-83. PubMed ID: 17074724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular cloning and functional characterization of the porcine extracellular domain of Receptor Activator of NF-κB Ligand (sRANKL).
    Böcker W; Radic T; Schönitzer V; Haasters F; Mutschler W; Schieker M
    Gene; 2012 Jan; 492(1):296-304. PubMed ID: 22062001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Porphyrin Derivatives Inhibit the Interaction between Receptor Activator of NF-κB and Its Ligand.
    Chypre M; Madel MB; Chaloin O; Blin-Wakkach C; Morice C; Mueller CG
    ChemMedChem; 2017 Oct; 12(20):1697-1702. PubMed ID: 28885764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.